Multiple myeloma (MM) is the second most common hematological malignancy of plasma
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …

This systematic review examines the available clinical data on CD34+ cell mobilization,
collection, and engraftment in multiple myeloma patients treated with the anti-CD38 …

Background Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line
treatment option for patients with newly diagnosed multiple myeloma. Whether the addition …

High-risk (HR) cytogenetics are associated with poor outcomes in newly diagnosed multiple
myeloma (NDMM), and dedicated studies should address this difficult-to-treat population …

Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell
transplantation (ASCT) has established itself as a core treatment for newly diagnosed …

We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K),
lenalidomide (R), and dexamethasone (d) without autologous stem cell transplant (ASCT) in …

Summary This Good Practice Paper provides recommendations for the diagnosis and initial
management of transplant‐eligible high‐risk myeloma patients. It describes recent updates …

Background Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory
multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K) …

Described as mollities ossium in 1844, the first reported case of a patient with multiple
myeloma (MM) was a 39 year-old-woman treated with an infusion of orange-peel, rhubarb …

Simple Summary Patients who are diagnosed with multiple myeloma are given an initial
sequence of treatments that usually, for those who are young and fit enough, includes high …